Another LAG-3 targeting mAb relatlimab (BMS-986016) alone and in combination with nivolumab is being tested in melanoma patients previously treated with anti-PD-1/PD-L1 therapy (NCT01968109). This evidence concerns the gene LAG3 and melanoma.